Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
暂无分享,去创建一个
M. Hidalgo | H. Pass | R. Maki | M. Hoque | D. Sidransky | A. Katz | S. Zacharoulis | C. Rodríguez-Galindo | E. Izumchenko | J. Stebbing | R. Ravi | K. Paz | A. Davies | N. Peled | L. Wexler | A. Bedi | D. Ciznadija | R. Ravi | H. Pass | E. Izumchenko | K. Paz | D. Ciznadija | I. Sloma | A. Katz | D. Vasquez-Dunddel | I. Ben-Zvi | J. Stebbing | W. McGuire | W. Harris | R. Maki | A. Gaya | A. Bedi | S. Zacharoulis | R. Ravi | L. H. Wexler | M. O. Hoque | C. Rodriguez-Galindo | N. Peled | A. Davies | R. Morris | M. Hidalgo | D. Sidransky | A. Gaya | I. Sloma | W. McGuire | D. Vasquez-Dunddel | R. Morris | I. Ben-Zvi | W. Harris | Harvey I. Pass | Ido Sloma | Nir Peled | Amos Katz | Justin Stebbing | William P. McGuire | Robert G. Maki | Angela M. Davies | Manuel Hidalgo
[1] P. Houghton,et al. Animal models for studying the action of topoisomerase I targeted drugs. , 1998, Biochimica et biophysica acta.
[2] M. Hidalgo,et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Hoque,et al. Patient‐derived xenografts as tools in pharmaceutical development , 2016, Clinical pharmacology and therapeutics.
[4] R. Hruban,et al. Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer , 2011, Clinical Cancer Research.
[5] I. Jurisica,et al. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] You Han Bae,et al. Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[7] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[8] Manuel Hidalgo,et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. , 2008, Cancer research.
[9] A. Valencia,et al. Transcriptional dissection of pancreatic tumors engrafted in mice , 2014, Genome Medicine.
[10] C. Iacobuzio-Donahue,et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer , 2010, British Journal of Cancer.
[11] Andrew M. K. Brown,et al. Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.
[12] I. Fichtner,et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. , 2004, European journal of cancer.
[13] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[14] J. Huse,et al. Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing , 2008, Brain pathology.
[15] A. Maitra,et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Sohrab P. Shah,et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.
[17] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[18] David Sidransky,et al. Patient-derived xenografts for individualized care in advanced sarcoma , 2014, Cancer.
[19] Chad A Shaw,et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.
[20] Philippe Dessen,et al. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[21] A. Berns,et al. Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.
[22] P. Houghton,et al. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. , 2004, European journal of cancer.
[23] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[24] John W. Cassidy,et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.
[25] Manuel Hidalgo,et al. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.
[26] A. Bardelli,et al. Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.
[27] Alfonso Valencia,et al. Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.
[28] S. Lam,et al. Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy , 2010, Clinical Cancer Research.
[29] Andrew L. Kung,et al. Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.
[30] A. Vincent-Salomon,et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.
[31] Richard Simon,et al. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. , 2010, Personalized medicine.
[32] J. Sarkaria,et al. Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer , 2014, Clinical Cancer Research.
[33] A. Jimeno,et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins , 2013, Molecular oncology.
[34] A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.